Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment
Clin Drug Investig (2018) 38:611-620
Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
European Respiratory Society International Congress (ERS). Milan, Italy. 9 - 13 sep 2017
Cost-effectiveness of tiotropium in the treatment of patients with asthma.
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.
Cost-effectiveness of a 13-valent conjugate pneumococcal vaccination program in COPD patients aged 50+ years in Spain.
18th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Milan, Italia. 7-11 nov 2015.
Int J Chron Obstruct Pulmon Dis. 2015;10:2027-36.
Economic Impact linked to the reduction of exacerbations when a treatment regime with inhaled antibiotics is switched to aztreonam lysine in patients with cystic fibrosis and chronic pulmonary infection caused by Pseudomonas aeruginosa.
17th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Amsterdam, Holland. 8-12 nov 2014.
Cost-effectiveness analysis of glycopyrronium bromide in the treatment of chronic obstructive pulmonary disease in Spain.
16th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Dublin, Irlanda. 2-6 nov 2013.
Análisis coste-efectividad de iloprost, epoprostenol y treprostinil en el tratamiento de la hipertensión arterial pulmonar: una actualización.
XXXIII Jornadas de Economía de la Salud (AES). Santander, España . 18-21 Junio 2013.
Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Appl Health Econ Health Policy. 2012;10(3):175-88.
Análisis coste-efectividad de budesónida/formoterol en tratamiento de mantenimiento y a demanda (Symbicort SMART®) frente a salmeterol/fluticasona más terbutalina, en el tratamiento del asma persistente en España.
XXVII Congreso Nacional de la Sociedad Española de Alergología e Inmunología Clínica. Madrid, España. 10-13 nov 2010.
Economic evaluation of iloprost, epoprostenol and treprostinil for the treatment of pulmonary arterial hypertension.
13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.
Factors affecting quality of life (QOL) of asthmatic patients in Spain.
13th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Prague, Czech Republic. 6-9 nov 2010.
Evaluación económica de iloprost, epoprostenol y treprostinil en el tratamiento de la hipertensión arterial pulmonar.
Sociedad Española de Cardiología (SEC) 2010. El Congreso de las Enfermedades Cardiovasculares. Valencia, España. 21-23 oct 2010.
Evaluación económica de iloprost, epoprostenol y treprostinil para el tratamiento de la hipertensión arterial pulmonar.
XXX Jornadas de Economía de la Salud (AES). Valencia, España. 22-25 jun 2010.
Pharmacoeconomics Span Res Art. 2010;7(4):163-75.